Health Catalyst, Inc. (HCAT) Q3 2024 Earnings Call Transcript Summary
Health Catalyst, Inc. (HCAT) Q3 2024 Earnings Call Transcript Summary
Year-over-year, technology revenue grew by 6%, totaling $48.11 million, while professional service revenue remained stable.The following is a summary of the Health Catalyst, Inc. (HCAT) Q3 2024 Earnings Call Transcript:
以下是Health Catalyst, Inc. (HCAT) 2024年第三季度業績會講話摘要：
Financial Performance:
財務表現:
Health Catalyst reported Q3 2024 total revenue of $76.4 million with an adjusted EBITDA of $7.3 million, both surpassing the midpoint of previous guidance.
Anticipates 2024 total revenue between $305 million and $311 million, and adjusted EBITDA expected to be between $25 million and $27 million.
Year-over-year, technology revenue grew by 6%, totaling $48.11 million, while professional service revenue remained stable.
For Q4 2024, projected total revenue is between $78 million and $84 million with adjusted EBITDA between $6.8 million and $8.8 million.
Health Catalyst報告2024年第三季度總營業收入爲7640萬美元，調整後的EBITDA爲730萬美元，均超過先前指引的中點。
預計2024年總營業收入介於30500萬和31100萬美元之間，調整後的EBITDA預計介於2500萬和2700萬美元之間。
科技業務收入同比增長6%，總計4811萬美元，而專業服務業務收入保持穩定。
2024年第四季度，預計總營業收入在7800萬和8400萬美元之間，調整後的EBITDA在680萬和880萬美元之間。
Business Progress:
業務進展:
Health Catalyst highlighted its closure of a definitive agreement to acquire Intraprise Health, enhancing its cybersecurity offerings. The purchase price is $43 million.
Announced strategic expansions with Wisconsin Statewide Health Information Network (WISHIN) and a new client partnership with CyncHealth.
Continuing migration to the Ignite platform, focusing on advancing AI capabilities and improving client operations.
Health Catalyst強調已完成收購Intraprise Health的最終協議，增強了其網絡安全概念的提供。購買價格爲4300萬美元。
宣佈與威斯康星州範圍健康信息網絡（WISHIN）的戰略擴展以及與CyncHealth的新客戶合作伙伴關係。
繼續遷移到Ignite平台，專注於推進人工智能能力並改善客戶業務。
Opportunities:
機會：
Expected double-digit revenue growth and a 50% increase in adjusted EBITDA for 2025, fueled by technology-led expansions and improved market conditions.
Expansion into higher-margin tech solutions while focusing on high-value client contracts, Trailing growth in more profitable segments of the market.
預計2025年營業收入將實現兩位數增長，調整後EBITDA將增長50%，主要受到以科技爲主導的擴展和市場環境改善的推動。
拓展高毛利科技解決方案，同時專注於高價值客戶合同，追蹤更具利潤性的市場細分增長。
Risks:
風險：
Noted challenges include longer deployment times for international and health information exchange clients, affecting quarterly revenue recognition.
Operational cost adjustments due to ongoing migrations and the implementation of new platforms may impact near-term financials.
注意到的挑戰包括針對國際和健康信息交換客戶的部署時間延長，影響季度營業收入確認。
由於持續遷移和新平台實施而導致的運營成本調整可能會影響短期財務狀況。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
